Subscribe
istock-931018720-gwengoat
GwenGoat / iStockphoto.com
30 November 2018Big Pharma

EFPIA concerned over SPC waiver amendments

Proposed amendments to the EU’s supplementary protection certificate (SPC) manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
European pharma body criticises SPC waiver vote
6 December 2018   The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
Big Pharma
EU committee approves SPC waiver
24 January 2019   The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.
Generics
European Council agrees on SPC manufacturing waiver
15 February 2019   The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
European pharma body criticises SPC waiver vote
6 December 2018   The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
Big Pharma
EU committee approves SPC waiver
24 January 2019   The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.
Generics
European Council agrees on SPC manufacturing waiver
15 February 2019   The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.

More on this story

Big Pharma
European pharma body criticises SPC waiver vote
6 December 2018   The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
Big Pharma
EU committee approves SPC waiver
24 January 2019   The Legal Committee of the European Parliament has voted in favour of the proposed supplementary protection certificate waiver.
Generics
European Council agrees on SPC manufacturing waiver
15 February 2019   The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent